Streetbeat News

Stock Prices

USO

A Trafigura-operated oil tanker caught fire after a Houthi strike near Yemen, according to Bloomberg. The incident could potentially disrupt oil shipments in the region, raising concerns over supply security. The United States Oil Fund (USO), an ETF that tracks the price of oil, may be affected by this event due to potential impacts on oil prices.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:20 pm

GBTC

Oliver Renick from Schwab Network suggests Bitcoin ETFs are being used by 'whales' as an exit strategy rather than an entry point for traditional investors. Market dynamics have shifted, with strong cash flow, profits, and dividends driving outperformance. Bitcoin, lacking these fundamentals, stands out as a risky asset. Despite the introduction of Spot ETFs, Bitcoin's integration into the financial system hasn't led to widespread adoption by traditional investors. The price of Bitcoin has declined despite substantial inflows into ETFs like Grayscale's Bitcoin Trust (GBTC), indicating a disconnect. Technical and market challenges make a bullish case for Bitcoin difficult.

Portfolio Pulse from Murtuza Merchant

January 26, 2024 | 8:16 pm

DINO

HF Sinclair Inc. (NYSE:DINO) has seen a slight increase in its stock price by 0.09% in the current market session to $53.77, but experienced a decrease over the past month and year by 1.15% and 1.77%, respectively. The company's P/E ratio of 4.67 is lower than the industry average of 10.44, which could suggest that the stock is undervalued or that investors expect lower future performance.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 8:15 pm

PINS

Evercore ISI Group analyst Mark Mahaney has maintained an Outperform rating on Pinterest (NYSE:PINS) and increased the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:14 pm

MRK

Merck & Co Inc (NYSE:MRK) reported that Keytruda, its cancer drug, showed a significant improvement in disease-free survival for patients with advanced bladder cancer post-surgery in the Phase 3 AMBASSADOR/KEYNOTE-123 trial. The data, presented at the ASCO GU Symposium, indicated a 31% reduction in disease recurrence or death risk compared to observation. Median DFS was 29.0 months for Keytruda versus 14.0 months for observation. The overall survival endpoint has not yet reached statistical significance. Keytruda's safety profile remained consistent with no new safety signals. MRK shares rose 0.53% to $120.77.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 8:14 pm

SHW

Evercore ISI Group analyst Greg Melich has maintained an Outperform rating on Sherwin-Williams (NYSE:SHW) and increased the price target from $355 to $360. This adjustment reflects a positive outlook on the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:11 pm

PANW

Evercore ISI Group analyst Peter Levine has maintained an Outperform rating on Palo Alto Networks (NASDAQ:PANW) and increased the price target from $315 to $405.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:08 pm

CRBP

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) stock is trading higher after announcing promising data from a Phase 1 clinical study of CRB-701 (SYS6002) at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The study targets metastatic urothelial cancer and other nectin-4 positive tumors, showing a 43% objective response rate and a 71% disease control rate at higher doses. CRB-701 demonstrated lower toxicity compared to enfortumab vedotin, with no severe adverse events or cases of drug-related peripheral neuropathy or skin rash reported. CRBP shares surged 257.80% to $30.20.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 8:05 pm

LMT

Lockheed Martin (NYSE:LMT) has seen significant options trading activity, with a mix of bearish and bullish sentiment among investors. Analysis of 14 trades shows 42% bullish and 57% bearish positions, with an equal number of puts and calls traded. Whales target a price range of $400 to $660 for LMT over the next 3 months. The stock is currently trading at $429, down 0.47%, with neutral RSI indicators. Analysts have varying ratings on LMT, with a consensus target price of $499.2. Notable ratings include RBC Capital's Sector Perform at $470, Susquehanna's Positive at $540, Citigroup's Buy at $508, Morgan Stanley's Equal-Weight at $503, and UBS's Neutral at $475.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 8:00 pm

DYN

Dyne Therapeutics is reportedly considering its options in response to takeover interest. The company, which is in the early stages of developing treatments for muscle diseases, has attracted attention from potential buyers. Dyne's shares have surged on the news, reflecting investor optimism about a possible acquisition deal.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:50 pm